New obesity drug survodutide shows breakthrough results for liver health

A new drug called survodutide is showing promising results in treating obesity and liver disease. Developed by Boehringer Ingelheim and Zealand Pharma, it has received fast-track approvals from both the US and European regulators. Early trials suggest it could help patients lose significant weight while improving liver health.

Survodutide works by activating two key receptors—GLP-1 and glucagon—which help break down fat in the liver. In Phase II trials, overweight and obese patients without diabetes lost up to 19% of their body weight over 46 weeks. Some also saw reductions in waist size (up to 16 cm) and blood pressure (up to 8.6 mmHg systolic and 4.8 mmHg diastolic).

The drug has also shown benefits for liver fibrosis. Up to 65% of adults with moderate to advanced fibrosis (F2 and F3 stages) experienced improvements in trials. While survodutide is not yet tested for alcohol-related liver disease, it is being studied for metabolic dysfunction-associated steatotic liver disease (MASH).

Regulatory agencies have taken notice. The US Food and Drug Administration (FDA) granted it fast-track status in 2021, and the European Medicines Agency (EMA) followed with an accelerated assessment in 2023. Phase III trials for MASH are ongoing, with detailed results available on clinical trial registries like ClinicalTrials.gov and EudraCT.

Survodutide's dual-action approach could offer a new option for patients struggling with obesity and related liver conditions. With regulatory support and strong Phase II results, further data from ongoing trials will determine its future role in treatment. The drug remains focused on MASH and obesity, with no current studies for alcohol-related liver disease.